Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.59 +3.3%	$6.11	$4.02 ▼ $15.10	$346.29M	2.09	1.74 million shs	900,358 shs
GERN Geron	$1.38 -2.1%	$1.44	$1.17 ▼ $5.06	$898.05M	0.65	11.21 million shs	14.47 million shs
MYGN Myriad Genetics	$5.53 +4.1%	$5.20	$3.81 ▼ $29.30	$489.46M	1.9	1.25 million shs	1.43 million shs
NVAX Novavax	$6.61 +4.9%	$6.78	$5.01 ▼ $17.81	$1.02B	2.69	6.28 million shs	5.97 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	+3.29%	-2.46%	+3.86%	+27.22%	-6.66%
GERN Geron	-2.13%	-10.97%	-10.68%	-13.21%	-68.20%
MYGN Myriad Genetics	+4.14%	+9.50%	+32.30%	-37.16%	-76.93%
NVAX Novavax	+4.92%	+1.85%	-10.55%	+10.54%	-48.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent Biosolutions	4.1952 of 5 stars	3.5	1.0	4.6	1.4	2.5	1.3
GERN Geron	3.2776 of 5 stars	3.4	1.0	1.3	2.4	1.7	0.6
MYGN Myriad Genetics	4.4519 of 5 stars	4.1	3.0	4.1	2.0	1.7	0.6
NVAX Novavax	4.5121 of 5 stars	3.1	2.0	4.7	1.4	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	3.00	Buy	$14.33	117.50% Upside
GERN Geron	2.78	Moderate Buy	$5.06	266.85% Upside
MYGN Myriad Genetics	2.13	Hold	$14.38	160.12% Upside
NVAX Novavax	2.29	Hold	$17.00	157.19% Upside

Current Analyst Ratings Breakdown

Latest EBS, NVAX, GERN, and MYGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/9/2025	NVAX Novavax	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$9.00 ➝ $7.00
5/8/2025	GERN Geron	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$4.00 ➝ $1.50
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/7/2025	MYGN Myriad Genetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $10.00
5/7/2025	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $7.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$1.04B	0.34	$1.98 per share	3.32	$8.91 per share	0.74
GERN Geron	$76.99M	11.42	N/A	N/A	$0.46 per share	3.00
MYGN Myriad Genetics	$837.60M	0.61	$1.04 per share	5.31	$7.70 per share	0.72
NVAX Novavax	$682.16M	1.57	N/A	N/A	($3.89) per share	-1.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.18	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
GERN Geron	-$174.57M	-$0.21	N/A	N/A	N/A	-119.54%	-47.86%	-26.78%	8/6/2025 (Estimated)
MYGN Myriad Genetics	-$127.30M	-$1.12	N/A	N/A	N/A	-12.20%	-4.95%	-3.39%	8/5/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.65	2.49	82.63	0.06	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)

Latest EBS, NVAX, GERN, and MYGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/7/2025	Q1 2025	GERN Geron	-$0.04	-$0.03	+$0.01	-$0.03	$49.88 million	$39.60 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.20	6.32	3.51
GERN Geron	0.44	7.87	6.97
MYGN Myriad Genetics	0.08	1.90	1.71
NVAX Novavax	N/A	2.06	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
GERN Geron	73.71%
MYGN Myriad Genetics	99.02%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	3.20%
GERN Geron	7.42%
MYGN Myriad Genetics	2.10%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	52.54 million	Optionable
GERN Geron	70	636.92 million	589.66 million	Optionable
MYGN Myriad Genetics	2,700	92.18 million	90.24 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable

EBS, NVAX, GERN, and MYGN Headlines

Recent News About These Companies

Moderna’s Shares Gain in Premarket as New Flu Shot Shows Promising Results

July 1 at 2:12 PM | tokenist.comT

Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?

July 1 at 10:01 AM | zacks.com

Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade

June 27, 2025 | zacks.com

Vaccines and antibodies up for debate at CDC advisory panel meeting

June 26, 2025 | reuters.com

Novavax Approval Process a Potential ‘Harbinger’ of Threat to FDA Integrity: Former Regulators

June 26, 2025 | biospace.comB

Novavax, Inc. (NVAX) latest stock news and headlines - Yahoo Finance

June 25, 2025 | uk.finance.yahoo.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

June 24, 2025 | zacks.com

Novavax Shareholders Approve Key Proposals at Annual Meeting

June 24, 2025 | tipranks.com

Notable healthcare headlines for the week: Eli Lilly, Novavax and Sarepta Therapeutics in focus

June 22, 2025 | msn.com

Novavax Faces Challenges Amid Stock Decline

June 21, 2025 | tipranks.com

Novavax (NVAX) Ascends While Market Falls: Some Facts to Note

June 20, 2025 | zacks.com

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

June 19, 2025 | zacks.com

Novavax slips as Citi launches with Sell rating on pipeline concerns

June 17, 2025 | seekingalpha.com

Novavax slips as Citi launches with Sell rating on pipeline concerns

June 17, 2025 | msn.com

Novavax (NASDAQ:NVAX) Shares Gap Down - Should You Sell?

June 17, 2025 | marketbeat.com

Novavax (NASDAQ:NVAX) Earns Sell Rating from Analysts at Citigroup

June 17, 2025 | marketbeat.com

Novavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Moderate Buy" by Brokerages

June 17, 2025 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Novavax (NVAX) and Intuitive Surgical (ISRG)

June 14, 2025 | theglobeandmail.com

Novavax: New Vaccine, Same Old Story - Still A Sell

June 13, 2025 | seekingalpha.com

Novavax, Inc. (NASDAQ:NVAX) Shares Sold by SG Americas Securities LLC

June 13, 2025 | marketbeat.com

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

June 12, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS, NVAX, GERN, and MYGN Company Descriptions

Emergent Biosolutions NYSE:EBS

$6.59 +0.21 (+3.29%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$6.56 -0.04 (-0.53%)

As of 08:17 AM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Geron NASDAQ:GERN

$1.38 -0.03 (-2.13%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$1.40 +0.02 (+1.45%)

As of 08:20 AM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Myriad Genetics NASDAQ:MYGN

$5.53 +0.22 (+4.14%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$5.52 -0.01 (-0.11%)

As of 04:05 AM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Novavax NASDAQ:NVAX

$6.61 +0.31 (+4.92%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$6.62 +0.01 (+0.23%)

As of 08:25 AM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time